Pretreatment characteristics of 68 patients with MMM enrolled in 2 separate phase 2 lenalidomide treatment protocols at the Mayo Clinic (n = 27) and MDACC (n = 41)
. | Mayo Clinic . | MDACC . |
|---|---|---|
| Total number of study patients (male) | 27 (17) | 41 (22) |
| Median age in years (range) | 66 (40-76) | 65 (42-83) |
| No. of patients with AMM/PPMM/PTMM | 21/3/3 | 30/4/7 |
| Median disease duration in months (range) | 40 (1-307) | 6 (0-79) |
| No. of previously treated patients (%) | 25 (93) | 36 (88) |
| No. of patients with previous myelosuppressive therapy (%) | 18 (67) | 15 (37) |
| No. of patients with previous thalidomide therapy (%) | 8 (30) | 13 (32) |
| No. of patients with hemoglobin level below 100 g/L | 27 (100) | 19 (46) |
| No. of patients with red blood cell transfusion dependency (%) | 21 (78) | 13 (32) |
| Hemoglobin (g/L) range in untransfused patients | 83-97 | 73-148 |
| No. of splenectomized patients (%) | 1 (4) | 7 (17) |
| Median palpable spleen size in cm (range)* | 16 (0-31) | 3 (0-30) |
| No. of patients with constitutional symptoms (%)† | 10 (37) | 2 (5) |
| Median leukocyte count × 109/L (range) | 8.4 (1.8-84.4) | 10.3 (2.4-45.4) |
| Median platelet count × 109/L (range) | 299 (132-831) | 216 (34-901) |
| No. of patients with platelet count less than 100 × 109/L | 0 | 12 (29) |
| Median platelet count × 109/L (range) | 0 | 73 (34-93) |
| Median circulating blast percentage (range) | 1 (0-10) | 0 (0-10) |
| Median circulating CD34 cell count × 106/L (range) | 166.1 (2.8-5176.4) | Not done |
| Median serum lactate dehydrogenase level in U/L (range)‡ | 778 (267-1725) | 1110 (376-3300) |
| No. of patients with cytogenetic abnormalities (%) | 13 (48) | 17 (42) |
| No. of patients with JAK2 V617F (%) | 14 (56); n = 25 | 18 (51); n = 35 |
. | Mayo Clinic . | MDACC . |
|---|---|---|
| Total number of study patients (male) | 27 (17) | 41 (22) |
| Median age in years (range) | 66 (40-76) | 65 (42-83) |
| No. of patients with AMM/PPMM/PTMM | 21/3/3 | 30/4/7 |
| Median disease duration in months (range) | 40 (1-307) | 6 (0-79) |
| No. of previously treated patients (%) | 25 (93) | 36 (88) |
| No. of patients with previous myelosuppressive therapy (%) | 18 (67) | 15 (37) |
| No. of patients with previous thalidomide therapy (%) | 8 (30) | 13 (32) |
| No. of patients with hemoglobin level below 100 g/L | 27 (100) | 19 (46) |
| No. of patients with red blood cell transfusion dependency (%) | 21 (78) | 13 (32) |
| Hemoglobin (g/L) range in untransfused patients | 83-97 | 73-148 |
| No. of splenectomized patients (%) | 1 (4) | 7 (17) |
| Median palpable spleen size in cm (range)* | 16 (0-31) | 3 (0-30) |
| No. of patients with constitutional symptoms (%)† | 10 (37) | 2 (5) |
| Median leukocyte count × 109/L (range) | 8.4 (1.8-84.4) | 10.3 (2.4-45.4) |
| Median platelet count × 109/L (range) | 299 (132-831) | 216 (34-901) |
| No. of patients with platelet count less than 100 × 109/L | 0 | 12 (29) |
| Median platelet count × 109/L (range) | 0 | 73 (34-93) |
| Median circulating blast percentage (range) | 1 (0-10) | 0 (0-10) |
| Median circulating CD34 cell count × 106/L (range) | 166.1 (2.8-5176.4) | Not done |
| Median serum lactate dehydrogenase level in U/L (range)‡ | 778 (267-1725) | 1110 (376-3300) |
| No. of patients with cytogenetic abnormalities (%) | 13 (48) | 17 (42) |
| No. of patients with JAK2 V617F (%) | 14 (56); n = 25 | 18 (51); n = 35 |
Spleen size measured from left costal margin.
Constitutional symptoms included fever, drenching night sweats, and weight loss of more than 10% of ideal body weight.
Normal reference range for serum lactate dehydrogenase was 91-257 U/L at the Mayo Clinic and 313-618 U/L at M. D. Anderson Cancer Center.